Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicyResearchSafetyIndustry Why This Matters I need the article…
Cannabis Boom: Innovations Rise, Health Gains Lag | Mirage News
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. ResearchIndustryPainMedical TreatmentAging Why This Matters Clinicians need to understand that despite rapid cannabis…
Cannabis testing challenges persist as Virginia retail market nears
✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicySafetyTHCIndustry Why This Matters As Virginia's legal cannabis market expands, clinicians need to understand…
LIVE: News Patrol (10AM) | ANC (6 April 2026) – YouTube
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Media LiteracyEvidence-Based…
Regular cannabinoid use and inflammatory biomarkers: Systematic review and hierarchical meta-analysis.
Cannabis use is rising, with both therapeutic and harmful uses that might involve inflammation. Preclinical studies and findings in humans are inconsistent. ...
Cannabis and Anxiety Relief in Real-World Patients: A 45-Day Longitudinal Analysis
A 45-day longitudinal study tracked daily anxiety relief in 416 medical cannabis patients. Cannabis-use days showed larger same-day reductions, but the design limits causal conclusions. Here’s what the data support, and what they don’t.